Towards population-specific pharmacogenomics in the era of next-generation sequencing. Issue 8 (August 2021)

• Record Type: Journal Article
• Authors: Ji, Xiangjun; Ning, Baitang; Liu, Jinghua; Roberts, Ruth; Lesko, Larry; Tong, Weida; Liu, Zhichao; Shi, Tieliu
• Is Part Of: Drug discovery today. Volume 26:Issue 8(2021)
• Page Start: 1776
• Page End: 1783
• Publication Date: 2021-08
• Subjects: Pharmacogenomics -- Next-generation sequencing -- Population group -- Biomarkers; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2021.04.015
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: NGS has potential for applying preemptive pharmacogenomics (PGx) in a clinical setting. Population PGx can identify groups, like vulnerable one, for therapeutic intervention. Studies on PGx biomarkers in minority & vulnerable group are crucial for public health. Abstract: Pharmacogenomics (PGx) has essential roles in identifying optimal drug responders, optimizing dosage regimens and avoiding adverse events. Population-specific therapeutic interventions that tackle the genetic root causes of clinical outcomes are an important precision medicine strategy. In this perspective, we discuss next-generation sequencing genotyping and its significance for population-specific PGx applications. We emphasize the potential of NGS for preemptive pharmacogenotyping, which is crucial to population-specific clinical studies and patient care. We also provide examples that use publicly available population-based genomics data for population-specific PGx studies. Last, we discuss the remaining challenges and regulatory efforts towards improvements in this field.